CMS Off-Label Cancer Drug Policy Will Have "Very Narrow" Focus

Policy decision for covering unapproved, non-compendial indications for cancer drugs is still pending, but will not mean a "sea change" in reimbursement, agency official says. Real issue is "unorganized" approach to off-label use as a whole in the U.S.